Les perspectives thérapeutiques des cytokines en matière d'allergie respiratoire [Therapeutic perspectives of cytokines in respiratory allergy conditions]
Details
Serval ID
serval:BIB_EE902FA5EBC7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Les perspectives thérapeutiques des cytokines en matière d'allergie respiratoire [Therapeutic perspectives of cytokines in respiratory allergy conditions]
Journal
Allergie et Immunologie
ISSN
0397-9148[print], 0397-9148[linking]
Publication state
Published
Issued date
1992
Volume
24
Number
6
Pages
197-198
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Abstract
Among the cytokines playing a role in asthma, IL-1 and TNF alpha or beta are important agents to be considered. IL-1 TNF alpha are produced by antigen-presenting cells. TNF alpha and beta are released by activated lymphocytes. Recently a natural inhibitor of IL-1 produced by monocytes or macrophages in the form of a 22-25 kD protein, which binds competitively to IL-1 receptors has been cloned and sequenced. This inhibitor is called the IL-1 receptors antagonist. Two types of TNF soluble receptors (55 and 75 kD) can be liberated from the surface of macrophages and neutrophils. These soluble receptors block both TNF alpha and beta activity. The respective roles of these cytokine inhibitors in the physiopathology of asthma need to be further defined, but new therapeutic perspectives are opening.
Keywords
Asthma/physiopathology, Asthma/therapy, Humans, Immunologic Factors/therapeutic use, Lymphokines/therapeutic use, Models, Biological, Receptors, Cell Surface/antagonists & inhibitors, Receptors, Cell Surface/physiology, Receptors, Immunologic/antagonists & inhibitors, Receptors, Interleukin-1, Receptors, Tumor Necrosis Factor, Respiratory Hypersensitivity/physiopathology, Respiratory Hypersensitivity/therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha/physiology
Pubmed
Create date
19/02/2010 20:40
Last modification date
20/08/2019 17:16